[Ip-health] LAST CALL - Support Access to University-Developed Medicines -- CALL FOR SIGNATORIES

[Caroline Gallant]

--
--
[ Picked text/plain from multipart/alternative ]
LAST CALL to join the initial signatories to support the Philadelphia
Consensus Statement.  Please email caroline.gallant(at)mail.mcgill.ca
to sign-on before Wednesday, November 1st.

We hope that this strongly supported statement will convince
universities to collectively adopt policies that will facilitate access
to university-developed medicines.  More information about the
Statement is below.

Since my last email over the listserve, we are pleased to report that
the list of individuals and organizations has swelled (list below).

Shortly, after we have publicly released the Statement, a website will
be up where individuals can continue to sign-on.  An email with the
details will be sent out.

-----
Subject: Support Access to University-Developed Medicines -- CALL FOR
SIGNATORIES

Organizations and individuals are invited to endorse the Philadelphia
Consensus Statement recently adopted by the international student group
Universities Allied for Essential Medicines (UAEM;
www.essentialmedicine.org).=A0 The full text of the statement is
attached.

We hope to gather as many signatures as possible in advance of a
broader public release slated for next Monday, October 23rd, 2006.

Individuals and organizations who have signed on to the Philadelphia
Consensus Statement thus far are listed below.

The Consensus Statement proposes three major changes to university
policies on health-related innovations:

I) Universities should promote equal access to research
II) Universities should promote research and development for neglected
diseases
III) Universities should measure research success according to impact
on human welfare

EQUAL ACCESS
Universities are key developers of drugs, vaccines or diagnostics. They
can leverage their intellectual property on these innovations to ensure
low-cost access in the developing world.

Mechanisms proposed to ensure access include: granting rights to
generic companies to manufacture and export university innovations to
developing countries, price reductions, non-patenting requirements in
low- and middle-income countries, and participation in patent pools.

RESEARCH FOR NEGLECTED DISEASES
Neglected diseases are those for which treatment options are inadequate
or do not exist and for which drug-market potential is insufficient to
attract a private-sector response.

Universities can adopt policies that remove barriers to neglected
diseases R&D. =A0Proposed policy changes include: engaging with
nontraditional partners, such as public-private partnerships or
developing country institutions, creating new opportunities for drug
development, and carving out neglected disease research exemptions in
any university patents or licenses.

MEASURING RESEARCH SUCCESS BY IMPACT ON HUMAN WELFARE
University technology transfer operations are usually evaluated using
simple, quantifiable criteria such as patents applied for and received,
licenses granted, and licensing revenue generated. Therefore, the
positive social impact of university innovations=97particularly in poor
countries=97goes largely unnoticed.

Universities can rectify this situation by collecting and making public
statistics on university intellectual property practices related to
global health access and collaborating to develop new technology
transfer metrics to better gauge access to public health goods and
innovation in neglected-disease research.


For more information on the Philadelphia Consensus Statement or UAEM,
please contact Caroline Gallant: caroline.gallant@mail.mcgill.ca

-----
LIST OF INITIAL SIGNATORIES TO THE PHILADELPHIA CONSENSUS STATEMENT

Individuals

SCIENCE & MEDICINE

Marcia Angell, Former Editor-in-Chief of the New England Journal of
Medicine; Member, Institute of Medicine; Senior Lecturer, Harvard
Medical School

Jerry Avorn, Professor of Medicine, Harvard Medical School

Pierre Baldi, Chancellor's Professor of Computer Science; Director of
Institute for Genomics and Bioinformatics, University of California,
Irvine

Solomon Benatar, Professor of Medicine, University of Cape Town;
Foreign Member, Institute of Medicine

Todd Capson, Associate Scientist, Smithsonian Tropical Research
Institute

Arachu Castro, Assistant Professor of Social Medicine, Harvard
University

Wim G.J. Hol, Professor, Biochemistry and Biological Structure,
Investigator Howard Hughes
Medical Institute, University of Washington

Peter Hotez, Director, Human Hookworm Vaccine Initiative; Walter G.
Ross Professor of Basic Science Research at The George Washington
University

Phyllis Kanki, Principal Investigator, Harvard PEPFAR; Professor of
Immunology and Infectious Disease, Harvard School of Public Health

J. Andrew McCammon, Investigator, Howard Hughes Medical Institute,
Joseph E. Mayer Professor of Theoretical Chemistry, Professor of
Pharmacology, UC San Diego

Jon F. Merz, Associate Professor, University of Pennsylvania School of
Medicine

Thomas E. Novotny, MD MPH, UCSF Global Health Sciences

Harold Simon, Professor of Family and Preventive Medicine, Chief of the
Division of International Health and Cross-cultural Medicine, UC San
Diego

Mark A. Wainberg, Professor of Medicine, Director, McGill AIDS Centre,
McGill University

Gavin Yamey, Senior Editor, PLoS Medicine; Consulting Editor, PLoS
Neglected Tropical Diseases


Nobel Laureates

John Polanyi, Professor, Nobel Laureate in Chemistry, University of
Toronto

John Sulston, Nobel Laureate in Medicine

Harold Varmus, Nobel Laureate in Medicine; Founder of Public Library of
Science (PLoS); Chairman of the Scientific Board of Grand Challenges in
Global Health


LAW

Yochai Benkler, Professor of Law, Yale Law School

James Boyle, William Neal Reynolds Professor of Law, Duke University

Edwin Cameron, Justice, South African Supreme Court of Appeal

Dan Hunter, Professor of Law, University of Melbourne Law School;
Visiting Associate Professor of Law, New York Law School

Beth Noveck, Director of the Institute for Information Law and Policy;
and Associate Professor, New York Law School

Mark A. Lemley, William H. Neukom Professor of Law, Stanford Law
School; Director, Stanford Program in Law, Science and Technology

Lawrence Lessig, Professor of Law at Stanford Law School

Peter Menell, Professor of Law and Director, Berkeley Center for Law &
Technology, University of California at Berkeley

Robert Merges, Wilson Sonsini Goodrich & Rosati Professor of Law and
Technology; Director, Berkeley Center for Law & Technology, University
of California at Berkeley

Carol Mimura, Assistant Vice Chancellor for Intellectual Property and
Industry Research Alliances, UC Berkeley

Kevin Outterson, Professor of Law, West Virginia University

Pamela Samuelson, Richard M. Sherman Distinguished Professor of Law;
Professor of Information Management; Chancellor's Professor; Director,
Berkeley Center for Law & Technology


PUBLIC HEALTH & POLICY

Dean Baker, Co-Director, Center for Economic and Policy Research

Alan Berkman, Founder of Health GAP, Associate Professor of
Epidemiology, Mailman School of Public Health,Columbia University

Art Caplan, Emmanuel and Robert Hart Professor of Bioethics, University
of Pennsylvania

Carlos M. Correa, Professor, University of Buenos Aires

Nils Daulaire, President and CEO, Global Health Council

Nicoletta Dentico, Policy and Advocacy Manager, Drugs for Neglected
Diseases Initiative

Paul Farmer, Presley Professor of Medical Anthropology, Harvard
University

Eva Harris, President, Sustainable Sciences Institute, Associate
Professor, University of California at Berkeley, School of Public
Health, Division of Infectious Diseases

Howard Hiatt, Professor of Medicine, Harvard Medical School; former
Dean of the Harvard School of Public Health

Jim Yong Kim, Fran=E7ois-Xavier Bagnoud Professor of Health and Human
Rights, Harvard University

Jamie Love, Director, Consumer Project on Technology

Peter Lurie, Deputy Director of Public Citizen's Health Research Group

Deborah McFarland, Professor, Rollins School of Public Health, Emory
University

Michael Merson, Director, Global Health Institute, Duke University

Richard R. Nelson, George Blumenthal Professor of International and
Public Affairs, Business, and Law, Emeritus, Columbia University

James Orbinski, Associate Professor Medicine and Political Science &
Munk Centre for International Studies, University of Toronto; former
International president of Medecins Sans
Frontieres/ Doctors Without Borders

Thomas Pogge, Professor of Philosophy, Columbia University

Josh Ruxin, Assistant Clinical Professor of Public Health, Columbia
University; Director, Millennium Villages Project Rwanda and the Access
Project

F.M. Scherer, Aetna Professor Emeritus of Government, Harvard University

Anthony So, Director, Program on Global Health and Technology Access,
Terry Sanford Institute of Public Policy, Duke University

Jill Sorenson, former Executive Director of Johns Hopkins Technology
Transfer Office, General Manager of Bilyan, LLC


CIVIL SOCIETY

Zackie Achmat, Founder and Chairman, Treatment Action Campaign

Professor Judith Blau, President of the U.S. Chapter of Sociologists
Without Borders

Paul Davis, Director, U.S. Government Relations, Health GAP (Global
Access Project)

Colleen Daniels, Project Coordinator, Health Action International Europe

Helene Gayle, President and CEO, CARE-USA; Immediate Past President,
International AIDS Society

Anand Grover, Project Director, Lawyers Collective HIV/AIDS Unit

Stephen Lewis, UN Special Envoy for HIV/AIDS in Africa

Chan Park, Advocacy Officer, Lawyers Collective HIV/AIDS Unit

Bernard Pecoul, Executive Director of the Drugs for Neglected Diseases
Initiative

Jonathan Quick, Former Director of Essential Drugs and Medicines Policy
at the World Health Organization; President and CEO of Management
Sciences for Health

Priti Radhakrishnan, Founder, Initiative for Medicines, Access &
Knowledge

Leonard S. Rubenstein, Executive Director, Physicians for Human Rights


Organizations
Organizations
African Services Committee
American Medical Student Association
Canadian HIV/AIDS Legal Network
Community HIV/AIDS Mobilization Project (CHAMP)
Dignitas International
Diverse Women For Diversity
European AIDS Treatment Group (EATG), Brussels, Belgium
Global AIDS Alliance
Global Health Council
Health GAP
Initiative for Medicines, Access, and Knowledge (I-MAK)
International Peoples Health Council (South Asia )
Lawyers Collective HIV/AIDS Unit
Partners in Health
Research Foundation For Science Technology & Ecology
Society for the Study of Social Problems
Sociologists without Borders
Southern Initiatives Journal of Sustainable Development
Stop HIV/AIDS in India Initiative
Student Campaign for Child Survival
Student Global AIDS Campaign

--
[ PhiladelphiaConsensusStatement.pdf of type application/pdf deleted ]
--
--
[ Picked text/plain from multipart/alternative ]

--